The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review Committee.
No clinically significant adverse events or.
The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review Committee. No clinically significant adverse events or
Valerio Therapeutics S A : Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.